Searchable abstracts of presentations at key conferences in endocrinology

ea0029p791 | Endocrine tumours and neoplasia | ICEECE2012

Over-expression of AIP protein in GH3 cells reduces cAMP signalling and Growth hormone secretion

Formosa R. , Xuereb-Anastasi A. , Vassallo J.

Mutations in the AIP gene have been linked to familial cases of pituitary adenomas (Vierimaa et al, 2006). Analysis of the protein support its role as a tumour suppressor since mutations cause a loss-of-function with reduced protein interactions and over-expression of wild-type (WT) AIP reduces cell proliferation (Leontiou et al, 2008). AIP interacts with a number of interesting proteins, among them are the phosphodiesterases, PDE4A5 and PDE2A, the G proteins, Gαq and G&#...

ea0029p828 | Endocrine tumours and neoplasia | ICEECE2012

Surgical management of primary hyperparathyroidism in a unit where Intra-operative PTH (IOPTH) monitoring is not routinely performed

Rughooputh N. , Vinayagam R. , Pain S.

Introduction: Parathyroidectomy is performed in primary hyperparathyroidism using either focussed approach or bilateral neck exploration depending upon the pre-operative localisation results. The type of localising investigations and utility of intra-operative adjuncts like IOPTH vary in individual units. In our unit, parathyroid sestamibi scan and neck ultrasound (USS) are done routinely for all cases, and SPECT/CT and CT or MRI are reserved for selective patients. This study...

ea0029p881 | Endocrine tumours and neoplasia | ICEECE2012

Prediction of remission of gestational trophoblastic disease based on initial levels of prolactin

Violante A. , Baptista A. , Luiz R\. , Belfort P.

Objective: A prospective study to research the relationship between initial levels of prolactin in the development and outcome of patients with gestational trophoblastic disease.Material and method: A longitudinal study including 51 women attending the Reference Center of Gestational Trophoblastic Neoplasia of Rio de Janeiro- Brazil, with complete mole, and comproved histopatologic examination. All women were followed up until remission was achieved. The...

ea0029p967 | Female Reproduction | ICEECE2012

Serum 17β-estradiol concentration and depression symptoms presence in climacteric women

Slopien R. , Maciejewska M. , Warenik-Szymankiewicz A.

We studied 74 women admitted to the Department of Gynecological Endocrinology University of Medical Sciences of Poznan because of climacteric symptoms. All the studied women were older than 40 years of age, all were still menstruating or had their last menstruation not later than 1 year ago.The aim of the study was evaluation of possible relationship between serum 17β-estradiol concentration and depression symptoms presence in climacteric women....

ea0029p1335 | Pituitary Basic | ICEECE2012

Multiple enhancers regulate expression of the human LHX3 gene in the developing pituitary

Park S. , Mullen R. , Rhodes S.

LHX3 is a LIM homeodomain transcription factor necessary for proper development of the pituitary and central nervous system. Patients with mutations in coding regions of the LHX3 gene have complex syndromes including combined pituitary hormone deficiency and nervous system defects resulting in symptoms such as dwarfism, thyroid insufficiency, infertility, and developmental delay. Although previous studies from our group and others have identified promoter and intronic elements...

ea0029p1721 | Thyroid (non-cancer) | ICEECE2012

Pattern of thyroid dysfunction in metabolic syndrome

Gyawali P. , Shrestha R. , Bhattarai P.

Introduction: Thyroid dysfunction is a common endocrine disorder affecting 300 million people around the world and over half are expected to be unaware of the condition. The number of people suffering from metabolic syndrome is also on the rise and it is estimated that a quarter of the world’s adults have metabolic syndrome. Thyroid dysfunction and metabolic syndrome (Met S) are both associated with atherosclerotic cardiovascular disease, hyperlipidemia and low grade infl...

ea0029p1746 | Thyroid (non-cancer) | ICEECE2012

Thyroid disorders and lipid abnormalities: An association between primary hypothyroidism and lipid profile pattern

Acharya D. , Dhital 1R. , Mahato R.

Introduction: The correlation between lipid profile changes & overt hypothyroidism is well established. Overt hypothyroidism is associated with increased risk for cardiovascular disease (CVD) as indicated by hypertension, elevated lipids levels, hypercholesterolemia, and particularly increased low-density lipoprotein cholesterol (LDL-C) levels. However, lipid profile alterations in primary and subclinical hypothyroidism are controversial. There are hardly any studies from ...

ea0029p1753 | Thyroid cancer | ICEECE2012

The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer cells

Chu R , van Hasselt C , Chen G

Both of peroxisome proliferator-activated receptor gamma (PPARγ) and estrogen receptor (ER) contribute to the development of thyroid cancer. Previously, the activation of ERα was found to promote the proliferation of thyroid cancer cells, whereas activation of either ERβ or PPARγ resulted in apoptosis of thyroid cancer cells. Furthermore, a transactivation between ER and PPARγ was reported in estrogen-responsive malignancy, such as breast cancer. Howev...

ea0026p58 | Endocrine tumours and neoplasia | ECE2011

A large adrenal tumour as a phenotypic manifestation of the Birt–Hogg–Dube syndrome

Juszczak A , Halliday D , Mihai R , Ali A

Introduction: The Birt–Hogg–Dube syndrome (BHDS) is a rare autosomal dominant genodermatosis characterised by presence of at least one of the following: benign skin fibrofolliculomas, lung cysts with recurrent pneumothoraces or renal tumours. The phenotypic constellation is due to heterozygous germline mutations of the tumour suppressor gene – FLCN, located on 17p11.2, encoding a 579 aminoacid protein termed folliculin. Case reports have described endocrine tumo...

ea0026p62 | Endocrine tumours and neoplasia | ECE2011

Injection systems for long-acting somatostatin analogs: a comparative assessment of preparation times and nurses' perceptions

Adelman D T , Burgess A , Davies P R

Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumours and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR). The aim of this study was to gain nurses’ insights on the use and ease of administration of SSA devices, including Somatuline Autogel new device (SA-ND), in Europe and the US.Methods/design: Seventy-seven qualified nurses with ≥3 S...